Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device
Retrieved on:
Sunday, March 5, 2023
MitraClip, Mitral valve, NYSE, Blood, Patient, MR, Mount Sinai Health System, Death, The New England Journal of Medicine, Medicine, Heart, Cardiology, Quality of life, German Hospital in Tirana, Mitral regurgitation, Risk, Survival, Policy, FDA, American College, American College of Cardiology, Heart failure, Medical imaging, Pharmaceutical industry
The results were presented at the American College of Cardiology's 72nd Annual Scientific Session together with World Congress of Cardiology (ACC.23/WCC) held in New Orleans (March 4-6, 2023).
Key Points:
- The results were presented at the American College of Cardiology's 72nd Annual Scientific Session together with World Congress of Cardiology (ACC.23/WCC) held in New Orleans (March 4-6, 2023).
- These data were simultaneously published in The New England Journal of Medicine .
- Prior to MitraClip, most heart failure patients with clinically significant secondary MR were treated with medication only.
- Patients in the COAPT trial received the first-generation MitraClip, the world's first transcatheter edge-to-edge repair (TEER) device.